Prelude Therapeutics Incorporated (PRLD)

Prelude Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	7	-	-	-	-
Gross Profit	7	-	-	-	-
Selling, General & Admin	28.72	28.88	30.65	26.96	10.59
Research & Development	118	103.39	92.89	86.78	48.18
Operating Expenses	146.71	132.28	123.54	113.74	58.76
Operating Income	-139.71	-132.28	-123.54	-113.74	-58.76
Other Non Operating Income (Expenses)	12.54	10.45	8.1	2.04	1.83
Pretax Income	-127.17	-121.83	-115.44	-111.69	-56.93
Net Income	-127.17	-121.83	-115.44	-111.69	-56.93
Net Income to Common	-127.17	-121.83	-115.44	-111.69	-56.93
Shares Outstanding (Basic)	76	60	47	46	12
Shares Outstanding (Diluted)	76	60	47	46	12
Shares Change (YoY)	25.60%	27.41%	2.87%	269.03%	647.86%
EPS (Basic)	-1.68	-2.02	-2.44	-2.43	-4.56
EPS (Diluted)	-1.68	-2.02	-2.44	-2.43	-4.56
Free Cash Flow	-103.65	-110.58	-86.75	-85.85	-46.8
Free Cash Flow Per Share	-1.37	-1.83	-1.83	-1.86	-3.75
Gross Margin	100.00%	-	-	-	-
Operating Margin	-1995.91%	-	-	-	-
Profit Margin	-1816.76%	-	-	-	-
Free Cash Flow Margin	-1480.74%	-	-	-	-
EBITDA	-137.94	-131.11	-122.22	-112.82	-58.22
D&A For EBITDA	1.77	1.17	1.32	0.92	0.54
EBIT	-139.71	-132.28	-123.54	-113.74	-58.76

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q